Skip to main content

Toward Translation of Nanotechnology Cancer Interventions (TTNCIs)

TTNCI’s enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. These awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

  • PURDUE UNIVERSITY –Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
  • MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY– PEAMOtecan, a novel chronotheranostic polymeric drug for brain cancer with potential multi-prong drug delivery capability
  • UNIVERSITY OF GEORGIA – Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
  • STANFORD UNIVERSITY – Rapid and affordable magneto-nanosensors for ctDNA-guided lung cancer management
  • FRED HUTCHINSON CANCER RESEARCH CENTER – Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing
  • UNIVERSITY OF WISCONSIN-MADISON – Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
  • UNIVERSITY OF NORTH CAROLINA CHAPEL HILL – Toward translation of nanaoformulated Paclitaxel-Platinum combination 
  • MASSACHUSETTS GENERAL HOSPITAL – High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer